Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) saw a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 5,600 shares, a growth of 21.7% from the July 15th total of 4,600 shares. Based on an average trading volume of 7,000 shares, the short-interest ratio is presently 0.8 days.
Advaxis Price Performance
OTCMKTS ADXS opened at $3.38 on Monday. Advaxis has a 1-year low of $1.02 and a 1-year high of $51.60. The firm has a market capitalization of $6.14 million, a P/E ratio of -33.80 and a beta of 2.07. The stock has a fifty day moving average of $3.70.
Get Advaxis alerts:Advaxis (OTCMKTS:ADXS – Get Rating) last issued its quarterly earnings data on Wednesday, June 8th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter. The company had revenue of $0.25 million for the quarter.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on shares of Advaxis in a research note on Tuesday, July 26th. They set a "sell" rating on the stock.Advaxis Company Profile
(Get Rating)
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Further Reading
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- MarketBeat: Week in Review 8/8 – 8/12
- 2 Important Retail Stock Battles to Watch
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.